Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service CGM & insulin pump management cases in New York: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (248 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 266 | 27,959 | 46% |
| 2020 | 276 | 25,701 | 48% |
| 2021 |
CGM setup and interpretation codes identify who prescribes diabetes technology. Professional codes (what the surgeon bills): CPT 95249, 95250, 95251.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 17% of the cases CMS names in New York; 227 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New Jersey | 303 | 39,418+16%/yr | +16%/yr | 37.1 | 99% | 69,600 in 2030+10%/yr |
| Pennsylvania | 334 |
CGM & insulin pump management in every state, and its device makers · Every procedure market in New York · Every state · Compare with New Jersey
| 2025 est. |
| ≈ 64,300 |
| – |
| 2026 est. | ≈ 70,300 | – |
| 338 |
| 34,553 |
| 51% |
| 2022 | 388 | 40,819 | 53% |
| 2023 | 427 | 48,329 | 55% |
| 2024 | 496 | 58,834 | 57% |
| 2025 from claims | – | 64,265 58,978–67,993 | 58% |
| 2026 forecast | – | 70,257 61,815–81,073 | 58% |
| 2027 forecast | – | 76,483 65,384–91,144 | 59% |
| 2028 forecast | – | 83,246 69,461–101,932 | 59% |
| 2029 forecast | – | 90,592 73,992–113,611 | 60% |
| 2030 forecast | – | 98,569 78,967–126,315 | 60% |
In 2025, 11% hospital outpatient, 89% office. The share outside the hospital has moved −5 pts since 2019.
| 37,842+26%/yr |
| +26%/yr |
| 27.2 |
| 80% |
| 63,900 in 2030+9.1%/yr |
| Massachusetts | 240 | 25,322+25%/yr | +25%/yr | 26.4 | 64% | 50,400 in 2030+12%/yr |
| Connecticut | 137 | 10,569+19%/yr | +19%/yr | 31.3 | 79% | 18,600 in 2030+9.9%/yr |
| New Hampshire | 60 | 7,226+35%/yr | +35%/yr | 31.5 | 56% | 14,600 in 2030+12%/yr |
| Maine | 30 | 2,429+36%/yr | +36%/yr | 15.1 | 18% | 4,270 in 2030+9.9%/yr |
| Rhode Island | 19 | 1,789+12%/yr | +12%/yr | 19.2 | 87% | 3,570 in 2030+12%/yr |
| Vermont | 14 | 1,742+68%/yr | +68%/yr | 15.1 | 23% | 4,210 in 2030+16%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Abbott leads with 33% of company spending on these surgeons in 2025, level with 2024.
In 2025, 9 companies reported engagement with New York’s surgeons worth $783K in consulting, speaking, meals and travel tied to these products, about $1,578 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 37 clearances and approvals in the category, 33 recalled product lines (8 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.